Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease

by Arne Carlsen, Roald Omdal, Kristian Øgreid Leitao, Kjetil Isaksen, Anne Kristine Hetta, Lars Normann Karlsen, Lars Aabakken, Nils Bolstad, David Warren, Knut E.A. Lundin, Tore Grimstad
Published 2018-03-01